Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer

Shelley Dranko; Connie Kinney; Ramesh K. Ramanathan

doi:10.3816/CCC.2006.n.040

Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer

Shelley Dranko, Connie Kinney, Ramesh K. Ramanathan

Hematology/Oncology

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Cetuximab is a monoclonal antibody that specifically blocks the epidermal growth factor receptor pathway. Cetuximab is now a standard drug to treat refractory advanced colorectal cancer.The most common side effect is a rash, seen in most patients. Ocular toxicity is uncommon. We report 2 cases of ocular toxicity characterized by blepharitis and conjunctivitis related to cetuximab administration. Strategies for management are discussed.

Original language	English (US)
Pages (from-to)	224-225
Number of pages	2
Journal	Clinical colorectal cancer
Volume	6
Issue number	3
DOIs	https://doi.org/10.3816/CCC.2006.n.040
State	Published - Sep 2006

Keywords

Blepharitis
Epidermal growth factor receptor
Erythema
Itchiness
Tearing
Trichomegaly

ASJC Scopus subject areas

Oncology
Gastroenterology

Access to Document

10.3816/CCC.2006.n.040

Cite this

@article{e58d6a8942254035a24273acb73ce618,

title = "Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer",

abstract = "Cetuximab is a monoclonal antibody that specifically blocks the epidermal growth factor receptor pathway. Cetuximab is now a standard drug to treat refractory advanced colorectal cancer.The most common side effect is a rash, seen in most patients. Ocular toxicity is uncommon. We report 2 cases of ocular toxicity characterized by blepharitis and conjunctivitis related to cetuximab administration. Strategies for management are discussed.",

keywords = "Blepharitis, Epidermal growth factor receptor, Erythema, Itchiness, Tearing, Trichomegaly",

author = "Shelley Dranko and Connie Kinney and Ramanathan, {Ramesh K.}",

year = "2006",

month = sep,

doi = "10.3816/CCC.2006.n.040",

language = "English (US)",

volume = "6",

pages = "224--225",

journal = "Clinical colorectal cancer",

issn = "1533-0028",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer

AU - Dranko, Shelley

AU - Kinney, Connie

AU - Ramanathan, Ramesh K.

PY - 2006/9

Y1 - 2006/9

N2 - Cetuximab is a monoclonal antibody that specifically blocks the epidermal growth factor receptor pathway. Cetuximab is now a standard drug to treat refractory advanced colorectal cancer.The most common side effect is a rash, seen in most patients. Ocular toxicity is uncommon. We report 2 cases of ocular toxicity characterized by blepharitis and conjunctivitis related to cetuximab administration. Strategies for management are discussed.

AB - Cetuximab is a monoclonal antibody that specifically blocks the epidermal growth factor receptor pathway. Cetuximab is now a standard drug to treat refractory advanced colorectal cancer.The most common side effect is a rash, seen in most patients. Ocular toxicity is uncommon. We report 2 cases of ocular toxicity characterized by blepharitis and conjunctivitis related to cetuximab administration. Strategies for management are discussed.

KW - Blepharitis

KW - Epidermal growth factor receptor

KW - Erythema

KW - Itchiness

KW - Tearing

KW - Trichomegaly

UR - http://www.scopus.com/inward/record.url?scp=33750199017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750199017&partnerID=8YFLogxK

U2 - 10.3816/CCC.2006.n.040

DO - 10.3816/CCC.2006.n.040

M3 - Article

C2 - 17026793

AN - SCOPUS:33750199017

SN - 1533-0028

VL - 6

SP - 224

EP - 225

JO - Clinical colorectal cancer

JF - Clinical colorectal cancer

IS - 3

ER -

Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this